Secondary Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia Following Prolonged Lenalidomide Maintenance in Multiple Myeloma

Read full text Summarise with VIRAT
Authors: Jessica Thomas, Yagnapriya Ammakola, Waqqas Tai, Afoma Anyadibe, Anuoluwa Oyetoran, Sarang Khan, Ishmael A. Jaiyesimi
Cited by: 0
References: 20

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Lenalidomide maintenance significantly improves survival in multiple myeloma (MM) but increases the risk of second primary malignancies (SPMs), with the most common hematologic SPMs being myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Secondary B-cell acute lymphoblastic leukemia (B-ALL) is rare. We describe a 62-year-old woman diagnosed with immunoglobulin G lambda MM with extramedullary disease. She achieved remission following induction with lenalidomide, carfilzomib, and dexamethasone, followed by autologous stem cell transplantation. Lenalidomide maintenance was continued for over 4 years, then discontinued due to fatigue. Nearly 1 year later, she presented with bruising and thrombocytopenia. Bone marrow biopsy confirmed Philadelphia chromosome-negative B-ALL with a complex karyotype. She achieved remission with mini-hyper-CVD (cyclophosphamide, vincristine, dexamethasone) plus inotuzumab ozogamicin and rituximab, followed by allogeneic transplantation. This case illustrates lenalidomide-associated B-ALL as a rare late complication of maintenance therapy in MM, underscoring the need for vigilance and early diagnostic evaluation.

Fields of Study & Subjects

Multiple and Secondary Primary Cancers Multiple Myeloma Research and Treatments Acute Lymphoblastic Leukemia research

Publication details

Journal / source
Journal of Medical Cases
Volume
17
Issue
5
Pages
183–189
Publication date
27 March 2026
Language
EN